Galenica demonstrates pleasing growth and improves EBIT guidance

• Galenica Group sales grew by 5.0% to CHF 1,995.4 million in the first half of 2025.
• Adjusted EBIT¹ increased by 10.9% to CHF 109.9 million – supported by positive one-time effects of CHF 5.4 million.
• Galenica is therefore raising its EBIT guidance and now expects growth between 7% and 9% (previously growth between 4% and 6%). 
• Guidance for 2025 sales growth remains unchanged at 3% to 5%, the dividend is expected to remain at least at the previous year’s level. 

Galenica recorded pleasing growth in a positive market environment in the first half of 2025. Both the “Products & Care” segment (+4.6%) and the “Logistics & IT” segment (+5.5%) contributed to the increase in sales of 5.0% to CHF 1,995.4 million. As a result, Galenica Group sales grew slightly stronger than the pharmaceutical market (+4.8%²) and the consumer healthcare market (+0.6%³).

Strong sales growth in prescription drugs

Following an increase of 4.7% by the end of April 2025, Galenica Group sales increased further in May and June 2025. Growth in the first half of the year was driven by strong demand for prescription drugs, including GLP-1-based⁴ weight loss products, as well as drugs associated with the heavy flu season early in the year. The good result was achieved despite one less day of sales compared to the same period in the previous year.

Reported EBIT increased by 6.2% to CHF 108.8 million, while adjusted EBIT¹ increased by 10.9% to CHF 109.9 million. In the first half of 2025, EBIT was supported by the pleasing sales growth as well as by positive one-off effects in the amount of CHF 5.4 million. Without these effects, adjusted EBIT¹ would have increased by 5.4%. The reason for this is that fines in two competition proceedings were significantly lower than originally expected, positively impacting the “Logistics & IT” segment.

Improved EBIT guidance for the second half of the year

Galenica confirms its 2025 outlook for consolidated net sales with growth of between 3% and 5% and the dividend at least at the same level as the previous year. Due to the strong growth in the first half of the year and positive one-time effects of CHF 5.4 million, Galenica now expects an EBIT¹ increase of between 7% and 9%. Prior to this, growth of between 4% and 6% had been expected.

In early July 2025, Galenica announced the acquisition of the diagnostics service provider Labor Team. As the closing date of the transaction has not yet been determined, the Labor Team Group is not yet included in the 2025 guidance.

Key figures of the Galenica Group in the first half of 2025

1) Excluding the effects of IFRS 16 and IAS 19 (details of the adjusted key figures in the half year report 2025)

2) IQVIA, Pharmaceutical Market Switzerland, YTD June 2025.

3) IQVIA, Consumer Health Market Switzerland, YTD June 2025.

4) GLP-1 stands for glucagon-like peptide 1, a hormone produced in the intestine and which plays an important role in regulating blood sugar levels.

Detailed information in the half year report 2025:

• Management report of the Galenica Group
• Management report for the Products & Care segment
• Management report for the Logistics & IT segment
• Key figures

Upcoming dates
23 October 2025: Galenica Group sales update
28 October 2025: Galenica Investor Day 2025
22 January 2026: Galenica Group sales update

For further information, please contact:

Welcome to the Galenica network!
Around 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally.

Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com.